Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 849-863 , October 2006

Treating very early rheumatoid arthritis

  • Karim Raza, MRCP, PhD (Clinical Senior Lecturer)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: 44 1214146778; Fax: 44 1214146794.
  • Mike Salmon, FRCPath, PhD (Professor of Experimental Rheumatology)

References 

  1. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. British Journal of Rheumatology. 1993;32:97–103
  2. Harrison BJ, Symmons DP, Brennan P, et al. Natural remission in inflammatory polyarthritis: issues of definition and prediction. British Journal of Rheumatology. 1996;35:1096–1100
  3. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford). 2002;41:793–800
  4. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. The Journal of Rheumatology. 1991;18:1298–1306
  5. Wolfe F, Hawley DJ. The long term outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. The Journal of Rheumatology. 1998;25:2108–2117
  6. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis and Rheumatism. 2001;44:2737–2745
  7. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis and Rheumatism. 2001;44:2707–2710
  8. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1:1108–1111
  9. Bukhari M, Harrison B, Lunt M, et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis and Rheumatism. 2001;44:1248–1253
  10. Welsing PM, Landewe RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism. 2004;50:2082–2093
  11. Wick MC, Lindblad S, Klareskog L, Van Vollenhoven RF. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description. Annals of the Rheumatic Diseases. 2004;63:848–852
  12. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis and Rheumatism. 2003;48:64–71
  13. Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Annals of the Rheumatic Diseases. 1999;58:510–513
  14. Mikuls TR, O'Dell J. The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis and Rheumatism. 2000;43:464–465
  15. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. The Journal of Clinical Investigation. 1997;99:439–446
  16. Pilling D, Akbar AN, Girdlestone J, et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. European Journal of Immunology. 1999;29:1041–1050
  17. Salmon M, Pilling D, Borthwick NJ, Akbar AN. Inhibition of T cell apoptosis – a mechanism for persistence in chronic inflammation. The Immunologist. 1997;5:87–92
  18. Buckley CD, Pilling D, Lord JM, et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends in Immunology. 2001;22:199–204
  19. Buckley CD, Amft N, Bradfield PF, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. Journal of Immunology (Baltimore, Md.: 1950). 2000;165:3423–3429
  20. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. Arthritis and Rheumatism. 2005;52:2975–2983
  21. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism. 1998;41:1552–1563
  22. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681
  23. Schumacher HR, Kitridou RC. Synovitis of recent onset. A clinicopathologic study during the first month of disease. Arthritis and Rheumatism. 1972;15:465–485
  24. Schumacher HR, Bautista BB, Krauser RE, et al. Histological appearance of the synovium in early rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1994;23:3–10
  25. Konttinen YT, Bergroth V, Nordstrom D, et al. Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis. Annals of the Rheumatic Diseases. 1985;44:549–555
  26. Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Research and Therapy. 2005;7:R784–R795
  27. Firestein GS. Pathogenesis of rheumatoid arthritis: how early is early?. Arthritis Research and Therapy. 2005;7:157–159
  28. Cush JJ. Early arthritis clinics: if you build it will they come?. The Journal of Rheumatology. 2005;32:203–207
  29. The HERA study group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. The American Journal of Medicine. 1995;98:156–168
  30. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with ‘second-line’ antirheumatic drugs. A randomized, controlled trial. Annals of Internal Medicine. 1996;124:699–707
  31. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309–318
  32. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis and Rheumatism. 2002;46:347–356
  33. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568–1573
  34. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis and Rheumatism. 2004;50:2072–2081
  35. Proudman SM, Conaghan PG, Richardson C, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis and Rheumatism. 2000;43:1809–1819
  36. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58:220–225
  37. Verstappen SM, Jacobs JW, Bijlsma JW, et al. Five-year follow-up of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis and Rheumatism. 2003;48:1797–1807
  38. Maillefert JF, Combe B, Goupille P, et al. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Annals of the Rheumatic Diseases. 2003;62:764–766
  39. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The New England Journal of Medicine. 1995;333:142–146
  40. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis and Rheumatism. 2005;52:3360–3370
  41. Harris ED. Prednisolone in early rheumatoid arthritis: an antiinvasive effect. Arthritis and Rheumatism. 2005;52:3324–3325
  42. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases. 2004;63:797–803
  43. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine. 2000;343:1586–1593
  44. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism. 2004;50:3432–3443
  45. Breedveld FC, Kavanaugh AF, Cohen SB, et al. Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA) plus methotrexate vs. adalimumab alone or methotrexate alone: The Premier study. Arthritis and Rheumatism. 2004;50:4096–4097
  46. Conaghan PG, Quinn MA, O'Connor P, et al. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?. Arthritis and Rheumatism. 2002;46:1971–1972
  47. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2005;52:27–35
  48. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis and Rheumatism. 2005;52:3381–3390
  49. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nature Immunology. 2005;6:1191–1194
  50. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. Journal of Immunology (Baltimore, Md.: 1950). 2001;167:1072–1080
  51. Nishikawa SI, Hashi H, Honda K, et al. Inflammation, a prototype for organogenesis of the lymphopoietic/hematopoietic system. Current Opinion in Immunology. 2000;12:342–345
  52. Nanki T, Hayashida K, El Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. Journal of Immunology (Baltimore, Md.: 1950). 2000;165:6590–6598
  53. Suzuki Y, Rahman M, Mitsuya H. Diverse transcriptional response of CD4(+) T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4(+) T cells. Journal of Immunology (Baltimore, Md.: 1950). 2001;167:3064–3073
  54. Scheel-Toellner D, Wang K, Henriquez NV, et al. Cytokine-mediated inhibition of apoptosis in non-transformed T cells and neutrophils can be dissociated from protein kinase B activation. European Journal of Immunology. 2002;32:486–493
  55. Reparon-Schuijt CC, van Esch WJ, van Kooten C, et al. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis and Rheumatism. 2000;43:1115–1121
  56. Brennan F, Foey A. Cytokine regulation in RA synovial tissue: role of T cell/macrophage contact-dependent interactions. Arthritis Research. 2002;4(supplement 3):S177–S182
  57. Brennan FM, Hayes AL, Ciesielski CJ, et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:31–41
  58. Paulus HE, Machleder HI, Levine S, et al. Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage. Arthritis and Rheumatism. 1977;20:1249–1262
  59. Ueo T, Tanaka S, Tominaga Y, et al. The effect of thoracic duct drainage on lymphocyte dynamics and clinical symptoms in patients with rheumatoid arthritis. Arthritis and Rheumatism. 1979;22:1405–1412
  60. Vaughan JH, Fox RI, Abresch RJ, et al. Thoracic duct drainage in rheumatoid arthritis. Clinical and Experimental Immunology. 1984;58:645–653
  61. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis and Rheumatism. 1997;40:217–225
  62. Bucht A, Larsson P, Weisbrot L, et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clinical and Experimental Immunology. 1996;103:357–367
  63. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 1988;31:315–324
  64. Singh JA, Pando JA, Tomaszewski J, Schumacher HR. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naive patients. The Journal of Rheumatology. 2004;31:1281–1285
  65. Jakubzick C, Choi ES, Kunkel SL, et al. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1- and Th2-type pulmonary granuloma fibroblasts. The American Journal of Pathology. 2003;162:1475–1486
  66. Kaufman J, Sime PJ, Phipps RP. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-gamma and IL-13, and implications for fibrosis. Journal of Immunology (Baltimore, Md.: 1950). 2004;172:1862–1871
  67. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. The Journal of Clinical Investigation. 1999;104:777–785
  68. Relic B, Guicheux J, Mezin F, et al. Il-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. Journal of Immunology (Baltimore, Md.: 1950). 2001;166:2775–2782
  69. Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. The Journal of Experimental Medicine. 1991;173:569–574
  70. Parsonage G, Falciani F, Burman A, et al. Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. Thrombosis and Haemostasis. 2003;90:688–697
  71. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Annals of the New York Academy of Sciences. 2003;987:140–149
  72. Machold KP, Nell VP, Stamm TA, et al. The Austrian Early Arthritis Registry. Clinical and Experimental Rheumatology. 2003;21:S113–S117
  73. Speyer I, Hazes JM, Breedveld FC. Recruitment of patients with early rheumatoid arthritis – the Netherlands experience. The Journal of Rheumatology, Supplement. 1996;44:84–85
  74. Raza K, Breese M, Nightingale P, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. The Journal of Rheumatology. 2005;32:231–238
  75. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism. 2002;46:357–365
  76. Green M, Marzo-Ortega H, McGonagle D, et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis and Rheumatism. 1999;42:2184–2188
  77. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism. 2000;43:155–163
  78. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Research. 2000;2:236–243
  79. Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64:1731–1736
  80. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:1831–1835
  81. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Annals of the Rheumatic Diseases. 2003;62:120–126
  82. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:894–898
  83. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906–914
  84. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine. 2003;9:1245–1250
  85. Choo-Kang BS, Hutchison S, Nickdel MB, et al. TNF-blocking therapies: an alternative mode of action?. Trends in Immunology. 2005;26:518–522
  86. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine. 2004;350:2572–2581
  87. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The New England Journal of Medicine. 2005;353:1114–1123
  88. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis and Rheumatism. 2004;50:1107–1116
  89. Brown AK, Wakefield RJ, Conaghan PG, et al. New approaches to imaging early inflammatory arthritis. Clinical and Experimental Rheumatology. 2004;22:S18–S25

PII: S1521-6942(06)00053-2

doi: 10.1016/j.berh.2006.05.005

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 849-863 , October 2006

Article Tools